Moon Surgical revealed the induction of medtech expert Chris Toth as an independent board director. Toth, possessing over two decades of experience in advancing and managing commercial operations, brings deep knowledge in business acceleration. Currently, he holds the position of EVP and group president at Baxter’s Kidney Care division. He will continue to helm the organization, rebranded as “Vantive,” as CEO following its acquisition by Carlyle Group.
Previously, Toth was the CEO of Varian, driving its merger with Siemens Healthineers. During his 20-year tenure at Varian, he undertook various leadership roles, notably as the president of global commercial and field operations.
“Welcoming Chris to our board marks a pivotal juncture for Moon Surgical,” expressed Anne Osdoit, CEO of Moon Surgical. “His unrivaled expertise in scaling corporate ventures on a global scale, along with his leadership acumen, will be instrumental as we bring the Maestro system to market and enhance the capability of surgical teams around the world.”
Based in Paris, Moon Surgical stands among the top 10 surgical robotics firms to watch in 2024, as recognized by MassDevice. The company’s innovation, Maestro, is designed as a robotic adjunct to conventional laparoscopy, enhancing precision and control. Crafted to seamlessly integrate with existing medical practices, this versatile system improves operating room throughput and supports alternative workforce approaches.
Earlier this year, the FDA granted approval for the commercial launch of Maestro.
“I firmly believe in the unique value proposition and strategic model of Moon Surgical,” Toth commented. “I’m privileged to be part of Moon Surgical’s board and to contribute to their goal of revolutionizing surgical procedures with the Maestro system.”